2 февр. 2024 г. · During the final quarter of 2023, sales of Humira—which once sat pretty as the world's best-selling drug—plunged nearly 41% to $3.3 billion ...

17 мар. 2022 г. · AbbVie's drug is the highest-selling pharmaceutical product in history, earning nearly $200 billion since its late 2002 US approval.

The Global Drug sales of Humira stood at USD 14,496.73 Millions in 2023. The indicator recorded a historical decline (CAGR) of11% between 2020 to 2023 and ...

3 июн. 2024 г. · The IL-23 inhibitor Skyrizi, first approved in 2019 by the FDA, brought in $7.7 billion in sales last year, itself a jump of 50% on its 2022 ...

22 мая 2024 г. · This statistic illustrates the revenue of pharmaceutical product Humira from 2011 to 2023. In 2023, AbbVie's top product generated 14.4 billion US dollars of ...

12 июл. 2024 г. · In 2021, before losing key patent protections, Humira raked in $20.6 billion in revenue, representing 14% growth from the prior year. In 2023, ...

24 мая 2024 г. · Skyrizi generated $7.7 billion in 2023, for indications such as plaque psoriasis, Crohn's disease and psoriatic arthritis. With expected ...

1 мая 2024 г. · Humira revenue plunged more than 30% to $2.3 billion during the first quarter, according to AbbVie. For years, AbbVie has built up a wall of ...

18 июн. 2024 г. · Humira, an arthritis medication with indications for colitis and psoriasis is the world's best-selling drug, but while its efficacy and ...

Global Humira net revenues of $2.270 billion decreased 35.9 percent on a reported basis, or 35.2 percent on an operational basis. · Global Skyrizi net revenues ...